CDC director slams agency's response to COVID-19 pandemic

Rochelle P. Walensky, MD, MPH, director of the Centers for Disease Control and Prevention (CDC), slammed the agency for failing to respond to the COVID-19 pandemic quickly enough, according to a report from The New York Times.

Her remarks came during a senior staff meeting Aug. 17, with Walensky, formerly chief of the Division of Infectious Diseases at Massachusetts General Hospital and professor of medicine at Harvard Medical School, outlining a broad plan to reorganize the agency to meet public health needs and prevent future outbreaks. Facing heavy criticism for the CDC’s COVID-19 response, Walensky ordered an external review of the agency in April. Her message this week offered an unspecific plan to overhaul the CDC, released in a video to all CDC employees. 

“For 75 years, CDC. and public health have been preparing for Covid-19, and in our big moment, our performance did not reliably meet expectations,” she said Wednesday. “My goal is a new, public health, action-oriented culture at CDC that emphasizes accountability, collaboration, communication and timeliness.” 

Among the changes, Walensky announced the appointment of Mary K. Wakefield, a former Obama administration health official who will lead the CDC’s shift to a stronger public health focus, the NY Times reported. 

Walensky’s plan comes as the CDC is dealing with outbreaks of two other infectious diseases causing concern––monkeypox and polio.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.